ALK and acute myeloid leukemia: Unfortunately, because of the rarity of ALK fusions in AML, there are no existing prospective trial data to support prophylactic post-HSCT maintenance therapy in a MRD negative state for AML with ALK fusions, which has led to roadblocks in achieving insurance coverage of the medication.